Biogen Inc. (BIIB)
What changed this quarter
- Risk factors — 5 added · 14 removed · new: BIIB122 (LRRK2 inhibitor)(1) - Parkinson's +4
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Company overview
Biogen. A company of multiple-sclerosis and rare-neurological-disease drugs. It gained a new growth driver with approval of the Alzheimer's drug Leqembi.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Biogen Inc. is classified under the Biotech & Health sector. See peers below.
Biogen Inc. key financials
Based on SEC filings · latest quarter (TTM)
Tap a metric name to see its meaning in the glossary.
ETFs holding Biogen Inc.
Per SEC N-PORT · 2026-03-31 · by weight · factual
BIIB on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — valuation and growth vs the Biotech & Health average
Peers · Biotech & Health
BIIB FAQ
What is Biogen Inc. (BIIB)?
Biogen. A company of multiple-sclerosis and rare-neurological-disease drugs. It gained a new growth driver with approval of the Alzheimer's drug Leqembi.
What sector is Biogen Inc. in?
Biogen Inc. is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are Biogen Inc.'s key financials?
Based on the latest quarter (TTM) from SEC filings: Revenue growth (YoY) 1.2%, Operating margin 24.6%, Net margin 13.8%, ROE 8.7%, Debt-to-equity 0.42x. Definitions and interpretation are available on Stocklore.
Where can I analyze Biogen Inc. (BIIB) stock?
On Stocklore you can see BIIB's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, 45-day delay), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.